Article Test

Home  >  Medical Research Archives  >  Issue 149  > Different strategies in treatment of malignant cells
Published in the Medical Research Archives
Dec 2022 Issue

Different strategies in treatment of malignant cells

Published on Dec 21, 2022




Malignant cells build up a protective scaffold in form of fibrin meshwork surrounding the tumor cells and provide an extracellular matrix (ECM) consisting of proteoglycans, collagens, glycoproteins, and glycosaminoglycans. Simultaneously, they produce stem cells in an early cancer stadium, which gain the energy and oxygen for their metabolism from the anaerobic glycolysis and are therefore independent of arterial supply. Many publications show that heparins have a wide variety of efficiencies to tumor metabolism because they have the highest negative charge density of any known biological molecules. Therefore, they should be exogenously added in high dosages. In an ambulant trial with daily exogenously added heparins, methadone and a combined clopidogrel/aspirin therapy the survival probability over 12 months was significantly higher than without (p<0,001). Additionally, zoledronic acid was given as infusion every 2 months. This auxiliary treatment has the potential to support established therapies. With methadone, heparins, zoledronic acid and clopidogrel/aspirin we present as supplement to the oncological therapy a model in treatment of malignant cells.

Key words: malignant cells, methadone, heparin, zoledronic acid, anticoagulants.

Author info

F.w. Schardt, E. Henke, A. Zernecke-madsen

Have an article to submit?

Submission Guidelines

Submit a manuscript

Become a member

Call for papers

Have a manuscript to publish in the society's journal?